A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

T-MAXIMUM is currently focused on late-stage malignant tumors, and its lead program for recurrent glioma has received clearance to enter Phase II clinical trials. Over the next three years, the ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company ...

Two recent studies show the novel therapy works in people with multiple myeloma, but researchers are trying to minimize side ...

Closes $60 Million Series A Financing Round Backed by New and Existing Investors$92 Million Raised to Date Across Seed and Series A FinancingsSOUTH SAN ...

Biotechnology company Leucid Bio announced a strategic collaboration with Syenex, an open-source gene therapy platform firm.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...

T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase ...